Amazon Pharmacy on Monday formally launched its much-anticipated weight loss drug subscription program, offering patients access to branded and compounded GLP-1 medications including semaglutide and tirzepatide at prices the company claims are up to 40 percent below typical out-of-pocket costs at traditional pharmacies. The program, which pairs drug fulfillment with an online clinical consultation service, marks Amazon's most aggressive move yet into the fast-growing obesity treatment market.
The launch follows weeks of signaling from Amazon that it intended to capitalise on surging U.S. demand for GLP-1 receptor agonists, a class of drugs that has transformed obesity treatment since the approvals of Ozempic, Wegovy, and Mounjaro. Industry analysts estimate the U.S. weight loss drug market will exceed $30 billion annually by 2030, making it one of the most contested spaces in consumer healthcare.
Amazon's entry is expected to intensify pressure on telehealth startups that have built substantial businesses around GLP-1 prescribing and fulfillment. Shares of Hims & Hers Health fell in premarket trading Monday as investors weighed the competitive implications, with analysts at Jefferies noting that Amazon's logistics infrastructure and existing Prime membership base give it structural advantages that newer entrants cannot easily replicate.
The program will initially be available in 35 states, with Amazon indicating it plans to expand nationally by the third quarter of 2026. Patients will be required to complete an online health intake form reviewed by a licensed clinician before a prescription is issued. Amazon said it has partnered with a network of board-certified physicians and nurse practitioners to staff the service around the clock.
Pharmaceutical manufacturers Novo Nordisk and Eli Lilly declined to comment directly on the launch but have previously expressed concern about compounded versions of their branded drugs, which have proliferated since the FDA declared supply shortages. Amazon said it would offer both FDA-approved branded options and, where legally permissible, compounded alternatives through licensed 503B outsourcing facilities, a detail likely to draw further scrutiny from regulators and brand-name drug makers in the coming weeks.